Clinical research

Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials

EuroIntervention 2012;8:87-93. DOI: 10.4244/EIJV8I1A14

James B. Hermiller
James B. Hermiller1*, MD, FSCAI, FACC; Krishnankutty Sudhir2, MD, PhD; Robert J. Applegate3, MD; Ali Rizvi1, MD; John Wang4, MD; Paul C. Gordon5, MD; Manejeh Yaqub2, MD; Sherry Cao2, MS; Joanne M. Ferguson2, RN; Robert S. Smith, Jr.2, PhD; Poornima Sood2, MD, MBA, MPhil; Gregg W. Stone6, MD
1. The Heart Center of Indiana, Indianapolis, IN, USA; 2. Abbott Vascular, Santa Clara, CA, USA; 3. Wake Forest University Health Sciences, Winston-Salem, NC, USA; 4. Union Memorial Hospital, Baltimore, MD, USA; 5. The Miriam Hospital,

Aims: The impact of age on outcomes following everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) implantation was evaluated in a p

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

clinical researchageeverolimuspaclitaxel
Read next article
Percutaneous closure of atrial right-to-left shunt in patients with Ebstein’s anomaly of the tricuspid valve

Latest news